Dimensional Fund Advisors
CRNX icon

Dimensional Fund Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Dimensional Fund Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.9M Buy
852,258
+303,281
+55% +$13.5M 0.01% 1755
2025
Q4 		$25.6M Buy
548,977
+171,175
+45% +$7.62M 0.01% 1859
2025
Q3 		$15.7M Buy
377,802
+202,545
+116% +$6.48M ﹤0.01% 2117
2025
Q2 		$5.04M Buy
175,257
+155,534
+789% +$4.8M ﹤0.01% 2518
2025
Q1 		$662K Buy
+19,723
New +$737K ﹤0.01% 2961
2024
Q4 		– Sell
-392,196
Closed -$20M – 3347
2024
Q3 		$20M Sell
392,196
-154,563
-28% -$7.97M ﹤0.01% 1998
2024
Q2 		$24.5M Sell
546,759
-94,043
-15% -$4.34M 0.01% 1867
2024
Q1 		$30M Sell
640,802
-19,119
-3% -$748K 0.01% 1776
2023
Q4 		$23.5M Sell
659,921
-84,895
-11% -$2.6M 0.01% 1905
2023
Q3 		$22.2M Buy
744,816
+225,707
+43% +$4.65M 0.01% 1867
2023
Q2 		$9.35M Buy
519,109
+69,504
+15% +$1.39M ﹤0.01% 2290
2023
Q1 		$7.22M Sell
449,605
-59,243
-12% -$1.1M ﹤0.01% 2355
2022
Q4 		$9.31K Sell
508,848
-27,222
-5% -$480K ﹤0.01% 2234
2022
Q3 		$10.5M Sell
536,070
-17,801
-3% -$363K ﹤0.01% 2135
2022
Q2 		$10.3M Buy
553,871
+64,514
+13% +$1.29M ﹤0.01% 2176
2022
Q1 		$10.7M Buy
489,357
+143,913
+42% +$2.91M ﹤0.01% 2266
2021
Q4 		$9.81M Buy
345,444
+34,100
+11% +$841K ﹤0.01% 2317
2021
Q3 		$6.55M Buy
311,344
+126,051
+68% +$2.64M ﹤0.01% 2497
2021
Q2 		$3.49M Buy
185,293
+119,573
+182% +$2.1M ﹤0.01% 2710
2021
Q1 		$1M Buy
65,720
+41,825
+175% +$648K ﹤0.01% 3017
2020
Q4 		$337K Buy
+23,895
New +$333K ﹤0.01% 3159

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Dimensional Fund Advisors's CRNX Position: Q1 2026 in Review

Dimensional Fund Advisors increased its Crinetics Pharmaceuticals (CRNX) stake by 55% in Q1 2026, buying an estimated $13.5M and bringing the position to 852,258 shares worth $30.9M. The position accounts for 0.01% of the portfolio, ranked #1755.

Dimensional Fund Advisors first reported a position in CRNX in Q4 2020 and has held it in 21 quarters since. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Dimensional Fund Advisors held 852,258 shares of Crinetics Pharmaceuticals worth $30.9M as of Q1 2026.
  • Dimensional Fund Advisors bought 303,281 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $13.5M.
  • Crinetics Pharmaceuticals made up 0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #1755 holding.
  • Dimensional Fund Advisors first reported a position in Crinetics Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.